RA
MCID: RHM011
MIFTS: 82

Rheumatoid Arthritis (RA)

Categories: Bone diseases, Genetic diseases, Immune diseases, Rare diseases, Respiratory diseases

Aliases & Classifications for Rheumatoid Arthritis

MalaCards integrated aliases for Rheumatoid Arthritis:

Name: Rheumatoid Arthritis 57 12 74 43 73 36 29 54 6 42 3 15 37 62 17 71
Ra 57 43 73 3
Arthritis, Rheumatoid 43 44 39
Rheumatoid Arthritis, Susceptibility to 57 13
Arthritis or Polyarthritis, Rheumatic 12
Atrophic Arthritis 12

Characteristics:

OMIM®:

57 (Updated 05-Mar-2021)
Inheritance:
unproved inheritance


Classifications:



External Ids:

Disease Ontology 12 DOID:7148
OMIM® 57 180300
KEGG 36 H00630
ICD9CM 34 714.0
MeSH 44 D001172
NCIt 50 C2884
SNOMED-CT 67 156471009
MedGen 41 C0003873
UMLS 71 C0003873

Summaries for Rheumatoid Arthritis

MedlinePlus Genetics : 43 Rheumatoid arthritis is a disease that causes chronic abnormal inflammation, primarily affecting the joints. The most common signs and symptoms are pain, swelling, and stiffness of the joints. Small joints in the hands and feet are involved most often, although larger joints (such as the shoulders, hips, and knees) may become involved later in the disease. Joints are typically affected in a symmetrical pattern; for example, if joints in the hand are affected, both hands tend to be involved. People with rheumatoid arthritis often report that their joint pain and stiffness is worse when getting out of bed in the morning or after a long rest.Rheumatoid arthritis can also cause inflammation of other tissues and organs, including the eyes, lungs, and blood vessels. Additional signs and symptoms of the condition can include a loss of energy, a low fever, weight loss, and a shortage of red blood cells (anemia). Some affected individuals develop rheumatoid nodules, which are firm lumps of noncancerous tissue that can grow under the skin and elsewhere in the body.The signs and symptoms of rheumatoid arthritis usually appear in mid- to late adulthood. Many affected people have episodes of symptoms (flares) followed by periods with no symptoms (remissions) for the rest of their lives. In severe cases, affected individuals have continuous health problems related to the disease for many years. The abnormal inflammation can lead to severe joint damage, which limits movement and can cause significant disability.

MalaCards based summary : Rheumatoid Arthritis, also known as ra, is related to arthritis and autoimmune disease, and has symptoms including back pain, sciatica and muscle cramp. An important gene associated with Rheumatoid Arthritis is PTPN22 (Protein Tyrosine Phosphatase Non-Receptor Type 22), and among its related pathways/superpathways are Rheumatoid arthritis and NF-kappaB Signaling. The drugs Buprenorphine and Fentanyl have been mentioned in the context of this disorder. Affiliated tissues include Cartilage, joint and bone, and related phenotypes are joint stiffness and fatigue

Disease Ontology : 12 An arthritis that is an autoimmune disease which attacks healthy cells and tissue located in joint.

OMIM® : 57 Rheumatoid arthritis is an inflammatory disease, primarily of the joints, with autoimmune features and a complex genetic component. (180300) (Updated 05-Mar-2021)

MedlinePlus : 42 Rheumatoid arthritis (RA) is a form of arthritis that causes pain, swelling, stiffness and loss of function in your joints. It can affect any joint but is common in the wrist and fingers. More women than men get rheumatoid arthritis. It often starts in middle age and is most common in older people. You might have the disease for only a short time, or symptoms might come and go. The severe form can last a lifetime. Rheumatoid arthritis is different from osteoarthritis, the common arthritis that often comes with older age. RA can affect body parts besides joints, such as your eyes, mouth and lungs. RA is an autoimmune disease, which means the arthritis results from your immune system attacking your body's own tissues. No one knows what causes rheumatoid arthritis. Genes, environment, and hormones might contribute. Treatments include medicine, lifestyle changes, and surgery. These can slow or stop joint damage and reduce pain and swelling. NIH: National Institute of Arthritis and Musculoskeletal and Skin Diseases

CDC : 3 Rheumatoid arthritis, or RA, is an autoimmune and inflammatory disease, which means that your immune system attacks healthy cells in your body by mistake, causing inflammation (painful swelling) in the affected parts of the body. RA mainly attacks the joints, usually many joints at once. RA commonly affects joints in the hands, wrists, and knees. In a joint with RA, the lining of the joint becomes inflamed, causing damage to joint tissue. This tissue damage can cause long-lasting or chronic pain, unsteadiness (lack of balance), and deformity (misshapenness). RA can also affect other tissues throughout the body and cause problems in organs such as the lungs, heart, and eyes.

KEGG : 36 Rheumatoid arthritis (RA) is a common autoimmune disease that primarily manifests as chronic inflammatory arthropathy. Persistent synovitis leads to cartilage destruction, bone erosions and periarticular decalcification, subsequently resulting in impaired joint function. It is more common between the ages of 35 and 50 years, affecting three times more women than men. Susceptibility to RA is genetically determined with multiple genes contributing. Inheritance of HLA DRB1 alleles encoding a distinctive five-amino-acid sequence known as the "shared epitope" (SE) is the best characterized genetic risk factor. The mechanism by which the SE alleles contribute to the development of RA is not very clear. It has been postulated that the presence of these conserved sequences in the antigen-binding groove alters the way antigenic peptides are bound to and presented to T-cell lymphocytes. This, in turn, may trigger abnormal immune responses and lead to RA.

UniProtKB/Swiss-Prot : 73 Rheumatoid arthritis: An inflammatory disease with autoimmune features and a complex genetic component. It primarily affects the joints and is characterized by inflammatory changes in the synovial membranes and articular structures, widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, and by atrophy and rarefaction of bony structures.

PubMed Health : 62 About rheumatoid arthritis: There are many different rheumatic diseases, but rheumatoid arthritis is probably the most common. In rheumatoid arthritis, people usually have several permanently inflamed joints. This causes the joints to gradually become deformed and stiff. Over time the muscles also weaken. Someone with advanced rheumatoid arthritis may have difficulties with simple tasks such as washing themselves, eating with a knife and fork, or buttoning up a shirt. Other symptoms such as pain and fatigue can be very troublesome too. This disease can also affect other parts of the body, like the blood vessels or certain organs. Rheumatoid arthritis usually gradually worsens over the course of many years. Various treatments can relieve the pain and slow the progression of the disease. Early diagnosis and treatment can help to prevent damage to the joints.

Wikipedia : 74 Rheumatoid arthritis (RA) is a long-term autoimmune disorder that primarily affects joints. It typically... more...

Related Diseases for Rheumatoid Arthritis

Diseases in the Rheumatoid Arthritis family:

Rheumatoid Arthritis, Systemic Juvenile Juvenile Rheumatoid Arthritis

Diseases related to Rheumatoid Arthritis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1857)
# Related Disease Score Top Affiliating Genes
1 arthritis 34.2 SLC22A4 PTPN22 PADI4 IRF5 IL10 CIITA
2 autoimmune disease 33.3 PTPN22 PADI4 MIR146A IRF5 IL10 CIITA
3 palindromic rheumatism 32.8 PTPN22 PADI4
4 systemic lupus erythematosus 32.6 PTPN22 PADI4 MIR155 MIR150 MIR146A MALAT1
5 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 32.5 PTPN22 IL10
6 psoriatic arthritis 32.4 PTPN22 MIR146A IL10
7 bone inflammation disease 32.2 PTPN22 PADI4 MIR155 MIR146A IL10
8 connective tissue disease 31.9 MIR155 MIR150 MIR146A MIR132 IL10
9 multiple sclerosis 31.8 PTPN22 PADI4 MIR155 IL10 CIITA
10 b-cell lymphoma 31.7 MIR155 MALAT1 HOTAIR CIITA
11 diffuse large b-cell lymphoma 31.5 MIR155 MIR150 IL10 HOTAIR CIITA
12 disease by infectious agent 31.5 MIR155 MIR150 MIR146A IL10
13 primary biliary cholangitis 31.5 PTPN22 MIR155 MIR150 IRF5
14 hemophagocytic lymphohistiocytosis 31.4 IRF5 IL10 CD244
15 immune deficiency disease 31.3 MIR155 MIR150 MIR146A MIR132 IL10 CIITA
16 lipoprotein quantitative trait locus 31.3 MIR155 MIR150 MIR146A IL10 H19
17 arteries, anomalies of 31.2 MIR155 MIR150 MIR146A MIR132
18 chronic graft versus host disease 31.0 PADI4 IL10
19 myeloma, multiple 30.7 UCA1 MALAT1 IL10 HOTAIR H19
20 central nervous system vasculitis 30.6 PTPN22 IL10
21 leukemia, chronic lymphocytic 30.6 MIR155 MIR150 MIR146A MIR132 IL10
22 spinal disease 30.4 MIR155 MIR150 MIR146A
23 nervous system disease 30.3 MIR155 MIR150 MIR146A MIR132 IL10
24 degenerative disc disease 30.3 MIR155 MIR146A MIR132
25 cervical cancer 30.1 UCA1 MIR155 MIR146A MALAT1 HOTAIR H19
26 leukemia, acute myeloid 30.1 UCA1 MIR155 MIR150 MIR146A MALAT1 IL10
27 kidney cancer 30.0 MIR150 MALAT1 HOTAIR H19
28 thyroid carcinoma 30.0 UCA1 MALAT1 HOTAIR H19
29 retinitis pigmentosa 11 30.0 UCA1 MIR146A HOTAIR
30 central nervous system disease 29.9 MIR155 MIR150 MIR146A MIR132 H19
31 osteogenic sarcoma 29.8 UCA1 MALAT1 HOTAIR H19
32 pituitary adenoma 29.7 MIR132 MALAT1 HOTAIR H19
33 renal cell carcinoma, nonpapillary 29.7 UCA1 MIR155 MIR150 MALAT1 HOTAIR H19
34 esophageal cancer 29.5 UCA1 MIR146A MALAT1 IL10 HOTAIR H19
35 gallbladder cancer 29.5 UCA1 MALAT1 HOTAIR H19
36 gastric cancer 29.3 ZFAS1 UCA1 MIR155 MIR150 MIR146A MALAT1
37 oral squamous cell carcinoma 29.3 UCA1 MIR155 MIR146A MIR132 MALAT1 HOTAIR
38 hepatocellular carcinoma 29.0 ZFAS1 UCA1 MIR155 MIR150 MIR146A MIR132
39 ovarian cancer 28.8 ZFAS1 UCA1 MIR155 MIR150 MIR146A MALAT1
40 juvenile rheumatoid arthritis 12.0
41 rheumatoid arthritis, systemic juvenile 11.8
42 felty syndrome 11.7
43 rheumatoid arthritis interstitial lung disease 11.6
44 sjogren syndrome 11.5
45 systemic onset juvenile idiopathic arthritis 11.4
46 spondyloarthropathy 1 11.4
47 plica syndrome 11.4
48 synovitis 11.4
49 polyarticular onset juvenile idiopathic arthritis 11.4
50 fibromyalgia 11.4

Comorbidity relations with Rheumatoid Arthritis via Phenotypic Disease Network (PDN): (show all 32)


Active Peptic Ulcer Disease Acute Cystitis
Bronchiectasis Bronchitis
Chronic Rheumatic Pericarditis Conn's Syndrome
Decubitus Ulcer Deficiency Anemia
Esophagitis Felty Syndrome
Heart Disease Hypersensitivity Vasculitis
Hypertension, Essential Hypothyroidism
Idiopathic Interstitial Pneumonia Immune Deficiency Disease
Iron Deficiency Anemia Mononeuropathy of the Median Nerve, Mild
Neutropenia Olecranon Bursitis
Oral Candidiasis Osteoarthritis
Osteoporosis Perforated Corneal Ulcer
Postinflammatory Pulmonary Fibrosis Premature Ovarian Failure 7
Protein-Energy Malnutrition Scleritis
Sjogren Syndrome Spondyloarthropathy 1
Systemic Lupus Erythematosus Temporal Arteritis

Graphical network of the top 20 diseases related to Rheumatoid Arthritis:



Diseases related to Rheumatoid Arthritis

Symptoms & Phenotypes for Rheumatoid Arthritis

Human phenotypes related to Rheumatoid Arthritis:

31 (show all 16)
# Description HPO Frequency HPO Source Accession
1 joint stiffness 31 HP:0001387
2 fatigue 31 HP:0012378
3 fever 31 HP:0001945
4 arthralgia 31 HP:0002829
5 joint swelling 31 HP:0001386
6 weight loss 31 HP:0001824
7 vasculitis 31 HP:0002633
8 elevated c-reactive protein level 31 HP:0011227
9 elevated erythrocyte sedimentation rate 31 HP:0003565
10 rheumatoid arthritis 31 HP:0001370
11 rheumatoid factor positive 31 HP:0002923
12 polyarticular arthritis 31 HP:0005764
13 swan neck-like deformities of the fingers 31 HP:0006150
14 digital flexor tenosynovitis 31 HP:0012276
15 interphalangeal joint erosions 31 HP:0006252
16 anti-citrullinated protein antibody positivity 31 HP:0033034

Symptoms via clinical synopsis from OMIM®:

57 (Updated 05-Mar-2021)
Joints:
rheumatoid arthritis

Limbs:
rheumatoid nodules

Vascular:
rheumatoid vasculitis

Neuro:
rheumatoid vasculitic mononeuritis

Immunology:
hla-drb1 association

Pulm:
rheumatoid lung disease

Heme:
felty syndrome

Clinical features from OMIM®:

180300 (Updated 05-Mar-2021)

UMLS symptoms related to Rheumatoid Arthritis:


back pain, sciatica, muscle cramp

Drugs & Therapeutics for Rheumatoid Arthritis

PubMed Health treatment related to Rheumatoid Arthritis: 62

Rheumatoid arthritis is treated with both medication and non-drug approaches, such as physiotherapy . There are also various support aids available for making everyday tasks easier. Which of these treatments are suitable options will depend on, for example, how severe the inflammation and the symptoms are, how advanced the disease is, the expected progression of the disease – and how well previous treatments have worked. Medication can reduce inflammation and help keep the disease from getting worse, relieve symptoms like pain and swelling, and help people move their joints more easily again, or at least maintain joint flexibility for as long as possible. There is currently no cure for rheumatoid arthritis . Physiotherapy and sports can help improve or maintain flexibility, strength and joint function. Many types of sports are suitable for people who have rheumatoid arthritis , including cycling, brisk walking, dancing, aerobics, strength training , swimming and water aerobics. Occupational therapy can be used to maintain your flexibility and hand strength, and to learn how to cope with rheumatoid arthritis in everyday life. Psychological treatments are also sometimes used to help relieve pain and minimize the impact it has on everyday life. They are also intended to help relieve disease-related anxiety and depression that some people develop. Support aids are designed to help compensate for physical limitations and help with daily activities. These include orthopedic shoe inserts, grabbing aids and specially designed cutlery.

Drugs for Rheumatoid Arthritis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 491)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Buprenorphine Approved, Illicit, Investigational, Vet_approved Phase 4 52485-79-7 40400 644073
2
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
3
Ibuprofen Approved Phase 4 15687-27-1 3672
4
Naproxen Approved, Vet_approved Phase 4 22204-53-1 1302 156391
5
Triamcinolone Approved, Vet_approved Phase 4 124-94-7 31307
6
Alendronate Approved Phase 4 121268-17-5, 66376-36-1 2088
7
Bupivacaine Approved, Investigational Phase 4 38396-39-3, 2180-92-9 2474
8
Meloxicam Approved, Vet_approved Phase 4 71125-38-7 5281106 54677470
9
Milnacipran Approved, Investigational Phase 4 92623-85-3 65833
10
Levomilnacipran Approved, Investigational Phase 4 96847-54-0
11
Norepinephrine Approved Phase 4 51-41-2 439260
12
Etoricoxib Approved, Investigational Phase 4 202409-33-4 123619
13
Tramadol Approved, Investigational Phase 4 27203-92-5 33741
14
Omeprazole Approved, Investigational, Vet_approved Phase 4 73590-58-6 4594
15
Simvastatin Approved Phase 4 79902-63-9 54454
16
Minocycline Approved, Investigational Phase 4 10118-90-8 5281021
17
Denosumab Approved Phase 4 615258-40-7
18
Diclofenac Approved, Vet_approved Phase 4 15307-86-5 3033
19
Pheniramine Approved Phase 4 86-21-5 4761
20
Teriparatide Approved, Investigational Phase 4 52232-67-4 16133850
21
Diphenhydramine Approved, Investigational Phase 4 147-24-0, 58-73-1 3100
22
Promethazine Approved, Investigational Phase 4 60-87-7 4927
23
Calcium carbonate Approved, Investigational Phase 4 471-34-1
24
Betamethasone Approved, Vet_approved Phase 4 378-44-9 9782
25
Ticagrelor Approved Phase 4 274693-27-5 9871419
26
Aceclofenac Approved, Investigational Phase 4 89796-99-6 71771
27
Everolimus Approved Phase 4 159351-69-6 6442177 70789204
28
Bazedoxifene Approved, Investigational Phase 4 198481-32-2
29
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
30
Racepinephrine Approved Phase 4 329-65-7 838
31
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
32
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
33
Azathioprine Approved Phase 4 446-86-6 2265
34
Celecoxib Approved, Investigational Phase 4 169590-42-5 2662
35
Hydrocortisone acetate Approved, Vet_approved Phase 4 50-03-3
36
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 5754
37
Coal tar Approved Phase 4 8007-45-2
38
Ravulizumab Approved, Investigational Phase 4 1803171-55-2
39
Protein C Approved Phase 4
40
Entecavir Approved, Investigational Phase 4 142217-69-4 153941
41
Tofacitinib Approved, Investigational Phase 4 477600-75-2
42
Zoledronic Acid Approved Phase 4 118072-93-8 68740
43
Sulfasalazine Approved Phase 4 599-79-1 5353980 5359476
44
Leflunomide Approved, Investigational Phase 4 75706-12-6 3899
45
Certolizumab pegol Approved Phase 4 428863-50-7
46
rituximab Approved Phase 4 174722-31-7 10201696
47
Ergocalciferol Approved, Nutraceutical Phase 4 50-14-6 5280793
48
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4 1406-16-2
49
Maleic acid Experimental Phase 4 110-16-7 444266
50
Corticosterone Experimental Phase 4 50-22-6 5753

Interventional clinical trials:

(show top 50) (show all 2391)
# Name Status NCT ID Phase Drugs
1 A Multicenter, Open-Label, Proof-of-Activity Study of the Effect of Subcutaneous ACTEMRA on Inflamed Atherosclerotic Plaques in Patients With Rheumatoid Arthritis Unknown status NCT02659150 Phase 4 tocilizumab
2 Screening Protein Predictive of Response to Tumor Necrosis Factor-α Inhibitors Treatment in Chinese Rheumatoid Arthritis From "Real World" and Investigating Its Mechanism Through Signal Pathway Unknown status NCT02878161 Phase 4 methotrexate(necessary);leflunomide (permitted, not necessary);NSAIDs (permitted,not necessary);Glucocorticoids (permitted,not necessary)
3 The Effect of Six Months Adalimumab Treatment on Sick Leaves and Retirement in Patients With Rheumatoid Arthritis Who Are at a Risk of Losing Their Ability to Work Unknown status NCT01405326 Phase 4
4 Comparison of the Efficacy and Safety of Kunxian Capsule and Methotrexate for the Treatment of Rheumatoid Arthritis Unknown status NCT02764515 Phase 4 Kunxian Capsule;Methotrexate
5 Interventional Study on the Effectiveness and Safety of Intensive Exercise in Patients With RA Unknown status NCT00434200 Phase 4
6 Use of TNF-blocking Therapy in Combination With DMARDs in Patients With Early Rheumatoid Arthritis Unknown status NCT00908089 Phase 4 Trexan+Salazopyrin+Oxiklorin+prednisolone + infliximab;Trexan+Salazopyrin+Oxiklorin+prednisolone + placebo
7 Prospective Clinical Study to Observe the Efficacy and Safety of Iguratimod in Rheumatoid Arthritis and Early Rheumatoid Arthritis Patients for 6 Months Treatment in China Unknown status NCT03855007 Phase 4 Iguratimod;MTX;HCQ;Pred
8 Targeting Synovitis in Early Rheumatoid Arthritis (TaSER). Intensive Management of Early Rheumatoid Arthritis Using Either Clinical or Musculoskeletal Ultrasound Assessment of Synovitis - a Randomised Study With Blinded Outcome Assessments Unknown status NCT00920478 Phase 4
9 Inhibition of Co-Stimulation in Rheumatoid Arthritis Unknown status NCT02652273 Phase 4 Abatacept
10 Uncontrolled Study to Evaluate Efficacy of Tocilizumab in Patients With Moderate or Severe Rheumatoid Arthritis and Candidates With a Biological Monotherapy Unknown status NCT02087696 Phase 4 Tocilizumab
11 Prospective Evaluation of Heart Function by Echocardiographic Study, Pro-brain Natriuretic Peptide Type B and Troponin T in Patients With Rheumatoid Arthritis and Ankylosing Spondylitis Pre and Post-TNF Blocker Unknown status NCT01072058 Phase 4 TNF blockers (infliximab, adalimumab, etanercept)
12 Comparison of the Effect of Etoricoxib and Diclofenac on Early Morning Activity in Rheumatoid Arthritis. Unknown status NCT01067430 Phase 4 Etoricoxib;Diclofenac
13 Ultrasonographic Monitoring of Response to Infliximab in Patients With Rheumatoid Arthritis Unknown status NCT01282528 Phase 4
14 Randomized Controlled Clinical Trial Evaluating Methotrexate + Biologic Versus Methotrexate, Salazopyrine and Hydroxychloroquine in Patients With Rheumatoid Arthritis and Insufficient Response to Methotrexate Unknown status NCT02714634 Phase 4 Methotrexate + biologic administration;methotrexate + salazopyrine + hydroxychloroquine administration
15 The Effect of Tocilizumab on the Cellular Immune Response to Seasonal Influnza Vaccine in Patients With Rheumatoid Arthritis Unknown status NCT01980836 Phase 4
16 Evaluation Effects of Treatment With IL-6R Inhibitor on Clinical Response and Biomarkers in Patients With Rheumatoid Arthritis (RA) Not Responding to DMARDs and/or a First Biological Agent. Unknown status NCT01835613 Phase 4
17 Effect of Monoclonal Anti-IL6 Antibody (Tocilizumab) on the Cardiovascular Risk in Patients With Rheumatoid Arthritis Unknown status NCT01752335 Phase 4
18 The Bucillamine Study of Holding Remission After Infliximab Dose-off in Patients With Rheumatoid Arthritis Receiving Methotrexate Unknown status NCT00716248 Phase 4 bucillamine;methotrexate
19 The Efficacy and Safety of Vaccination Against Pertussis. Tetanus and Diphtheria in Patients Suffering From Rheumatoid Arthritis Unknown status NCT01301703 Phase 4
20 Randomised, Multicenter, Open-label, Parallel-group Study Comparing Adalimumab 40 mg s.c. Eow Versus Infliximab 3 mg/kg i.v. Every 6 Weeks in Rheumatoid Arthritis Patients With Unsustainable Clinical Response to Infliximab 3 mg/kg Every 8 Weeks Unknown status NCT00216177 Phase 4 Infliximab;Adalimumab
21 Effects of Biological Treatment on Blood Pressure and Endothelial Function in Patients With Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis Unknown status NCT02132234 Phase 4 Etanercept;Adalimumab;Certolizumab;Infliximab
22 A Randomized, Double-blind Study to Evaluate the Efficacy and Safety of Iguratimod Alone or Iguratimod in Combination With Methotrexate Versus Methotrexate Alone in Patients With Rheumatoid Arthritis Unknown status NCT01548001 Phase 4 Iguratimod;Methotrexate
23 Cell Immunity Response to Vaccination Against Influenza in Patients With Rheumatoid Arthritis Unknown status NCT01002716 Phase 4
24 Rotation or Change of Biotherapy After First Anti-TNF Treatment Failure for Rheumatoid Arthritis Unknown status NCT01000441 Phase 4 infliximab, etanercept, adalimumab;abatacept, rituximab or tocilizumab
25 Therapeutic Drug Monitoring of Tocilizumab in Rheumatoid Arthritis Unknown status NCT03781310 Phase 4 Tocilizumab
26 The Comparative Study of Safety and Effectiveness of Intra-articular Injection of Tocilizumab and Compound Betamethasone in Rheumatoid Arthritis of the Knee Unknown status NCT03215407 Phase 4 Intra-articular Tocilizumab;Intra-articular Compound Betamethasone
27 NSAIDs vs. Coxibs in the Presence of Aspirin: Effects on Platelet Function, Endothelial Function, and Biomarkers of Inflammation in Subjects With Rheumatoid Arthritis and Increased Cardiovascular Risk or Cardiovascular Disease Unknown status NCT03699293 Phase 4 celecoxib 200mg capsule;naproxen sodium 550mg tablet;Aspirin 81mg tablet
28 Remission Induction in Very Early Rheumatoid Arthritis: a Comparison of Etanercept Plus Methotrexate Plus Steroid With Standard Therapy Unknown status NCT00523692 Phase 4 Etanercept, methotrexate and depomedrone;depemedrone
29 Prospective Randomized Multicentric Trial on Anti-TNFα Treatment and Infection Risk in the Perioperative Period During Elective Foot and Ankle Surgery in Patients With Rheumatoid Arthritis. Unknown status NCT02242474 Phase 4 Anti-TNF suspended perioperatively;Anti-TNFα continued perioperatively
30 Open-label, Pilot Protocol of Patients With Rheumatoid Arthritis Who Were Treated With H.P. Acthar Gel After an Incomplete Response to Combinations of DMARDs and Biologic DMRADs Unknown status NCT03082573 Phase 4 H.P. Acthar gel
31 Improving Influenza Immunization Responses in Rheumatoid Arthritis: A Strategy To Enhance Protection Against A Preventable Cause Of Death In An At Risk Population? Unknown status NCT02936180 Phase 4
32 A Randomized, Double-blind Study to Evaluate the Efficacy of Iguratimod Versus Placebo in Patients With Rheumatoid Arthritis on Magnetic Resonance Imaging (MRI) Unknown status NCT01893151 Phase 4 Iguratimod;Iguratimod placebo
33 A Randomized, Double-blind Study to Evaluate the Efficacy and Safety of Iguratimod or Leflunomide in Combination With Methotrexate in Patients With Active Rheumatoid Arthritis Unknown status NCT02275299 Phase 4 Iguratimod;Leflunomide;Methotrexate
34 Bone Resorption, Osteoclastogenesis and Adalimumab Unknown status NCT02035800 Phase 4 Adalimumab
35 Efficacy and Safety of Adalimumab 80 mg Every Other Week With Methotrexate Unknown status NCT01270035 Phase 4 Adalimumab
36 A Double Blind Randomized Controlled Trial to Compare Biannual Peripheral Magnetic Resonance Imaging, Radiography, and Standard of Care on Pharmacotherapeutic Escalation in Inflammatory Arthritis Unknown status NCT00808496 Phase 4
37 Rituximab (RTX) Therapy in Steroid Resistant Patients or Patients Relapsing After Intravenous Steroids With Active TAO Unknown status NCT02378298 Phase 4 Rituximab;Iv Methylprednisolone;peroral methylprednisolone and Methotrexate
38 Safety and Efficacy of Anti-Pandemic H1N1 Vaccination in Rheumatic Diseases Unknown status NCT01151644 Phase 4
39 Methotrexate Alone Versus Methotrexate in Combination With Adalimumab in Early Arthritis Unknown status NCT00291915 Phase 4 Adalimumab;Methotrexate
40 Adalimumab to Mitigate Cardiovascular Risk in RA Patients With Well-Controlled Joint Disease Unknown status NCT01893996 Phase 4 Adalimumab;Placebo
41 Humira Efficacy Response Optimization Study in Subjects With Active Rheumatoid Arthritis (HERO) Completed NCT00234897 Phase 4 adalimumab
42 Aiming for Remission in Rheumatoid Arthritis: a Randomized Trial Examining the Benefit of Ultrasonography in a Clinical TIght Control Regimen Completed NCT01205854 Phase 4
43 Can TNF-Alpha Incomplete Secondary Responders Attain a Safe and Efficacious Response By Switching to Certolizumab Pegol (Cimzia)? A Phase IV, Randomized, Multi-Center, Double-Blind, Twelve-Week Study Followed by a 12-Week Open-Label Phase Completed NCT01147341 Phase 4 Cimzia;Placebo
44 Multicentre Study To Evaluate Efficacy And Safety Of Buprenorphine Transdermal Patch (Norspan) In Chronic Non-Malignant Pain Of Moderate To Severe Intensity Due To Osteoarthritis, Rheumatoid Arthritis, Lower Back Pain And Joint / Muscle Pain, When Opioid Is Needed For Analgesia Completed NCT01961271 Phase 4 Buprenorphine transdermal patch
45 Phase IV STudy of Tacrobell in Active Rheumatoid Arthritis Completed NCT01746680 Phase 4 Tacrolimus with Methotrexate
46 Methotrexate Polyglutamate Levels as a Marker for the Clinical Outcome in the Treatment of Rheumatoid Arthritis A Multicenter, Randomized, Double-blind, Controlled Phase IV Trial Completed NCT00695188 Phase 4 methotrexate;methotrexate
47 Double-blind, Randomized, Placebo-controlled Study of Enbrel (Etanercept) in the Treatment of Rheumatoid Arthritis Subjects With Comorbid Disorders Completed NCT00132418 Phase 4 Enbrel;Placebo
48 A Phase 4, Multicenter, Open-Label, Assessor-Blinded Switch Study of the Efficacy and Safety of Infliximab (REMICADE) in Patients With Active Rheumatoid Arthritis Who Are Responding Inadequately to Etanercept (ENBREL) or Adalimumab (HUMIRA). Completed NCT00714493 Phase 4
49 Randomized Trial of 10 mg Versus 30 mg Per Week of Folic Acid in Combination With Methotrexate in Rheumatoid Arthritis Completed NCT01583959 Phase 4 Folic Acid;Placebo
50 A Randomized, Double-blind Placebo-controlled Study Of The Maintenance Of Efficacy Of Etanercept Plus Dmard(s) Compared With Dmard(s) Alone In Subjects With Rheumatoid Arthritis After Achieving An Adequate Response With Etanercept Plus Dmard(s) Completed NCT01578850 Phase 4 Etanercept;placebo

Search NIH Clinical Center for Rheumatoid Arthritis

Inferred drug relations via UMLS 71 / NDF-RT 51 :


ACETYLSALICYLATE SODIUM
adalimumab
anakinra
Aspirin
ASPIRIN PWDR
Auranofin
Aurothioglucose
Azathioprine
Captopril
celecoxib
Chloroquine
Chloroquine hydrochloride
chloroquine phosphate
choline salicylate
Cyclosporine
Diclofenac
Diclofenac Potassium
Diclofenac Sodium
Diflunisal
Enalapril
Enalapril Maleate
Enalaprilat
Etanercept
Etodolac
Fenoprofen
Fenoprofen Calcium
Fish Oils
Flurbiprofen
Flurbiprofen sodium
Gold
Gold Sodium Thiomalate
Hydroxychloroquine
Hydroxychloroquine Sulfate
Ibuprofen
Indomethacin
INDOMETHACIN PWDR
INDOMETHACIN SODIUM
Ketoprofen
KETOPROFEN PWDR
leflunomide
Methotrexate
Methotrexate Sodium
nabumetone
Naproxen
Naproxen sodium
oxaprozin
Penicillamine
Piroxicam
solufenum
Sulfasalazine
Sulindac
Thalidomide
tocilizumab
tofacitinib
Tolmetin
Tolmetin Sodium
valdecoxib

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Rheumatoid Arthritis cell therapies at LifeMap Discovery.

Cochrane evidence based reviews: arthritis, rheumatoid

Genetic Tests for Rheumatoid Arthritis

Genetic tests related to Rheumatoid Arthritis:

# Genetic test Affiliating Genes
1 Rheumatoid Arthritis 29 CD244 CIITA IL10 NFKBIL1 PADI4 PTPN22 SLC22A4

Anatomical Context for Rheumatoid Arthritis

The Foundational Model of Anatomy Ontology organs/tissues related to Rheumatoid Arthritis:

19
Joint

MalaCards organs/tissues related to Rheumatoid Arthritis:

40
Bone, Lung, T Cells, Endothelial, B Cells, Bone Marrow, Neutrophil
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Rheumatoid Arthritis:
# Tissue Anatomical CompartmentCell Relevance
1 Cartilage Temporomandibular Joint Affected by disease

Publications for Rheumatoid Arthritis

Articles related to Rheumatoid Arthritis:

(show top 50) (show all 33486)
# Title Authors PMID Year
1
Specific interaction between genotype, smoking and autoimmunity to citrullinated alpha-enolase in the etiology of rheumatoid arthritis. 57 6 61 54
19898480 2009
2
Association of a haplotype in the promoter region of the interferon regulatory factor 5 gene with rheumatoid arthritis. 6 57 54 61
17599733 2007
3
Functional SNPs in CD244 increase the risk of rheumatoid arthritis in a Japanese population. 6 57 61
18794858 2008
4
Gene-gene and gene-environment interactions involving HLA-DRB1, PTPN22, and smoking in two subsets of rheumatoid arthritis. 61 6 57
17436241 2007
5
A missense single-nucleotide polymorphism in a gene encoding a protein tyrosine phosphatase (PTPN22) is associated with rheumatoid arthritis. 57 6 54
15208781 2004
6
Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. 57 6
17554300 2007
7
An intronic SNP in a RUNX1 binding site of SLC22A4, encoding an organic cation transporter, is associated with rheumatoid arthritis. 6 57
14608356 2003
8
Identification of I kappa BL as the second major histocompatibility complex-linked susceptibility locus for rheumatoid arthritis. 57 6
12509789 2003
9
A regulatory variant in CCR6 is associated with rheumatoid arthritis susceptibility. 54 61 57
20453841 2010
10
REL, encoding a member of the NF-kappaB family of transcription factors, is a newly defined risk locus for rheumatoid arthritis. 54 61 57
19503088 2009
11
Investigation of genetic variation across the protein tyrosine phosphatase gene in patients with rheumatoid arthritis in the UK. 6 54 61
17170052 2007
12
Genetics of rheumatoid arthritis contributes to biology and drug discovery. 61 57
24390342 2014
13
Confirmation of association of FCGR3B but not FCGR3A copy number with susceptibility to autoantibody positive rheumatoid arthritis. 57 61
22290871 2012
14
Genetic basis of autoantibody positive and negative rheumatoid arthritis risk in a multi-ethnic cohort derived from electronic health records. 57 61
21211616 2011
15
Genome-wide association study meta-analysis identifies seven new rheumatoid arthritis risk loci. 61 57
20453842 2010
16
Genetic variants at CD28, PRDM1 and CD2/CD58 are associated with rheumatoid arthritis risk. 61 57
19898481 2009
17
Identification of AF4/FMR2 family, member 3 (AFF3) as a novel rheumatoid arthritis susceptibility locus and confirmation of two further pan-autoimmune susceptibility genes. 57 61
19359276 2009
18
Common variants at CD40 and other loci confer risk of rheumatoid arthritis. 57 54
18794853 2008
19
Association of the STAT4 gene with increased susceptibility for some immune-mediated diseases. 57 54
18759272 2008
20
Upregulated miR-146a expression in peripheral blood mononuclear cells from rheumatoid arthritis patients. 54 61 47
18759964 2008
21
Rheumatoid arthritis association at 6q23. 57 61
17982455 2007
22
Autoimmune-associated lymphoid tyrosine phosphatase is a gain-of-function variant. 6 54
16273109 2005
23
BLyS and APRIL in rheumatoid arthritis. 57 54
16239971 2005
24
PTPN22 genetic variation: evidence for multiple variants associated with rheumatoid arthritis. 54 57
16175503 2005
25
Polymorphisms in the interferon-gamma/interleukin-26 gene region contribute to sex bias in susceptibility to rheumatoid arthritis. 57 54
14558082 2003
26
Association of the -2849 interleukin-10 promoter polymorphism with autoantibody production and joint destruction in rheumatoid arthritis. 57 54
12847677 2003
27
Autoantibodies to GPI in rheumatoid arthritis: linkage between an animal model and human disease. 54 57
11477412 2001
28
Active conventional treatment and three different biological treatments in early rheumatoid arthritis: phase IV investigator initiated, randomised, observer blinded clinical trial. 61 42
33268527 2020
29
Trial of Upadacitinib or Abatacept in Rheumatoid Arthritis. 61 42
33053283 2020
30
Detection of T cell responses to a ubiquitous cellular protein in autoimmune disease. 57
25324392 2014
31
Polarization of the effects of autoimmune and neurodegenerative risk alleles in leukocytes. 57
24786080 2014
32
The autoimmune disease-associated PTPN22 variant promotes calpain-mediated Lyp/Pep degradation associated with lymphocyte and dendritic cell hyperresponsiveness. 6
21841778 2011
33
A polymorphism in the 3'-UTR of interleukin-1 receptor-associated kinase (IRAK1), a target gene of miR-146a, is associated with rheumatoid arthritis susceptibility. 61 47
20870441 2010
34
MicroRNA-146a expresses in interleukin-17 producing T cells in rheumatoid arthritis patients. 61 47
20840794 2010
35
Genome-wide association study of CNVs in 16,000 cases of eight common diseases and 3,000 shared controls. 57
20360734 2010
36
Platelets amplify inflammation in arthritis via collagen-dependent microparticle production. 57
20110505 2010
37
Combined effects of three independent SNPs greatly increase the risk estimate for RA at 6q23. 57
19417005 2009
38
Genome-wide association study and meta-analysis find that over 40 loci affect risk of type 1 diabetes. 6
19430480 2009
39
Cutting edge: the PTPN22 allelic variant associated with autoimmunity impairs B cell signaling. 6
19265110 2009
40
Meta-analysis of genome-wide association study data identifies additional type 1 diabetes risk loci. 6
18978792 2008
41
Mutation screening of PTPN22: association of the 1858T-allele with Addison's disease. 6
18301444 2008
42
Comprehensive evaluation of the genetic variants of interferon regulatory factor 5 (IRF5) reveals a novel 5 bp length polymorphism as strong risk factor for systemic lupus erythematosus. 6
18063667 2008
43
Two independent alleles at 6q23 associated with risk of rheumatoid arthritis. 57
17982456 2007
44
Genetic variation in PTPN22 corresponds to altered function of T and B lymphocytes. 6
17878369 2007
45
TRAF1-C5 as a risk locus for rheumatoid arthritis--a genomewide study. 57
17804836 2007
46
STAT4 and the risk of rheumatoid arthritis and systemic lupus erythematosus. 57
17804842 2007
47
Chronic polyarthritis caused by mammalian DNA that escapes from degradation in macrophages. 57
17066036 2006
48
MHC2TA single nucleotide polymorphism and genetic risk for autoimmune adrenal insufficiency. 6
16849401 2006
49
HLA-G 14-bp polymorphism regulates the methotrexate response in rheumatoid arthritis. 57
16906016 2006
50
High-density SNP analysis of 642 Caucasian families with rheumatoid arthritis identifies two new linkage regions on 11p12 and 2q33. 57
16691188 2006